Researchers affiliated to The AVONEX® Pregnancy Exposure Registry (Biogen) have published a case series of 306 pregnancy outcomes for a cohort of women with multiple sclerosis who used intramuscular interferon beta-1a during the first trimester. More information available here. Photo by Mufid Majnun on Unsplash
» Read more
See here for the latest announcement about the 2024 joint ENTIS-OTIS meeting in Nyborg, Denmark.
» Read more
In 2022, the European Society for Medical Oncology held a virtual meeting to gain insights from a multidisciplinary group of experts and develop statements about the management of breast cancer during pregnancy. The recommendations are available here. Photo by Anastasiia Chepinska on Unsplash
» Read more
The Italian Societies of Toxicology, Neuropsychopharmacology, Psychiatry, Obstetrics and Gynecology, Drug Addiction, and Addiction Pathology have published joint consensus recommendations regarding the management of depressive disorders in pregnancy. These recommendations focussed on five key areas including: (i) the importance of management of anxiety and depressive disorders in pregnancy; (ii) the overall risk of malformation with antidepressant and anxiolytic drugs; (iii) […]
» Read more
Researchers affiliated to the Poison Control Center and Teratology Information Center in Bergamo, Italy, have published a case series of regnancy and fetal outcomes following maternal use of long-acting injectable antipsychotics. More information is available here. Photo by Mufid Majnun on Unsplash
» Read more
Researchers from Teva Pharmaceuticals and St. Josef-Hospital (Bochum, Germany) have published the pregnancy and fetal outcomes for a cohort of 618 women who used glatiramer acetate in all three trimesters of pregnancy. More information can be found here.
» Read more
This year’s annual conference will be held at the Royal College of Surgeons in Ireland, in Dublin, from 31st August to the 2nd September. The conference organising committee at the Irish Medicines in Pregnancy Service (Rotunda Hospital, Dublin) have released the conference programme, which is available here.
» Read more
Researchers from the COVI-PREG research group have published data investigating the malformation risks following first trimester COVID-19 vaccination. More information is available here.
» Read more
Utilising data from the Colorado-based Children’s Hospital Immunodeficiency Program (CHIP), a team of researchers have published a retrospective comparative cohort study of pregnancy and fetal outcomes following first trimester integrase inhibitor use (dolutegravir, elvitegravir or raltegravir). The study describes increased risks of congenital anomalies among the first trimester integrase inhibitor exposed in comparison with those born to women with HIV […]
» Read more
Experts from 13 countries and professionally diverse backgrounds took part in the development of a series of recommendations focusing on the importance of including the study of infant neurodevelopment as a core feature of pregnancy drug safety studies. These recommendations outline the core neurodevelopmental outcomes, optimization of methodological approaches and barriers to conducting pregnancy drug safety studies including neurodevelopmental outcomes. […]
» Read more